Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Case Comprehensive Cancer Center
Daiichi Sankyo
Sumitomo Pharma America, Inc.
Mirati Therapeutics Inc.
Nektar Therapeutics
Incyte Corporation
Duke University